British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

GlaxoSmithKline (GSK) has announced the repurchase of 783,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part ...

With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...

UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...

More children stopped using steroid inhalers to control their asthma after GlaxoSmithKline withdrew Flovent from the market.

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses ...

Quarterly Net Profit at Rs. 262.87 crore in March 2025 up 35.17% from Rs. 194.48 crore in March 2024. EBITDA stands at Rs. 373.87 crore in March 2025 up 30.23% from Rs. 287.09 crore in March 2024.

Witty will act as a senior advisor to his successor, Stephen Hemsley, who served as UnitedHealth Group’s CEO from 2006 to ...

India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...